Chemomab Therapeutics Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Chemomab Therapeutics Ltd. (CMMB) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum of 4.09% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-23.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum · last filed 2026-03-23
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2022 was 1.75%, a 28.68% increase from fiscal 2021.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2021 was 1.36%, a 353.33% increase from fiscal 2020.
- Chemomab Therapeutics Ltd. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, minimum for fiscal 2020 was 0.30%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum 12 month |
|---|---|
| 2025-12-31 | 4.09% 20-F · filed 2026-03-23 |
| 2024-12-31 | 4.10% 20-F · filed 2025-04-04 |
| 2023-12-31 | 3.71% 20-F · filed 2024-03-28 |
| 2022-12-31 | 1.75% 10-K · filed 2023-03-20 |
| 2021-12-31 | 1.36% 10-K · filed 2022-03-30 |
| 2020-12-31 | 0.30% 10-K · filed 2021-03-09 |